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Abstract
Background: Radiotherapy is associated with a risk of subsequent neoplasms (SN) in childhood cancer survivors. It
has been shown that children’s thyroid glands are especially susceptible. The aim is to quantify the risk of a second
neck neoplasm after primary cancer radiotherapy with emphasis on thyroid cancer.
Methods: We performed a nested case–control study: 29 individuals, diagnosed with a solid SN in the neck region,
including 17 with thyroid cancer, in 1980–2002 and 57 matched controls with single neoplasms were selected from
the database of the German Childhood Cancer Registry. We investigated the risk associated with radiotherapy
exposure given per body region, adjusted for chemotherapy.
Results: 16/17 (94.1 %) thyroid SN cases, 9/12 (75 %) other neck SN cases and 34/57 (59.6 %) controls received
radiotherapy, with median doses of 27.8, 25 and 24 Gy, respectively. Radiotherapy exposure to the neck region
increased the risk of the other neck SNs by 4.2 % (OR = 1.042/Gy (95 %-CI 0.980-1.109)) and of thyroid SN by 5.1 %
(OR = 1.051/Gy (95 %-CI 0.984-1.123)), and radiotherapy to the neck or spine region increased the thyroid risk by
6.6 % (OR = 1.066/Gy (95 %-CI 1.010-1.125)). Chemotherapy was not a confounder. Exposure to other body regions
was not associated with increased risk.
Conclusions: Radiotherapy in the neck or spine region increases the risk of thyroid cancer, while neck exposure
increases the risk of any other solid SN to a similar extent. Other studies showed a decreasing risk of subsequent
thyroid cancer for very high doses; we cannot confirm this.
Keywords: Thyroid cancer, Second malignant neoplasm, Childhood cancer survivor, Radiotherapy, Case–control
study
Background
As a result of improved diagnostic procedures and pro-
gress in treatment in the past decades, about 81 % of
childhood cancer patients nowadays survive at least
15 years [1]. As a consequence, the importance of late
effects in the follow-up care of childhood cancer survi-
vors has increased. One of the most severe late effects is
the occurrence of a subsequent neoplasm (SN) [2, 3]. In
Germany, currently 4.7 % of childhood cancer patients
develop a second malignant neoplasm (SN) within
twenty-five years of the first neoplasm [1].
Chemotherapy and radiotherapy (RT) have been shown
to have a considerable impact on the risk of an SN
[2, 4–6]. Besides leukaemia and breast cancer, thyroid
cancer is most frequently associated with radiation
exposure [2]. Gul et al. [7] identified high doses
absorbed by the thyroid gland due to scattered radi-
ation during radiotherapy for breast cancer, lung can-
cer, Hodgkin’s lymphoma and tumours in the head
and neck region using CO60 teletherapy. An associ-
ation between the occurrence of thyroid adenomas
and the radiation dose received during childhood can-
cer treatment has been recently shown [8]. An update
from the Childhood Cancer Survivor Study (CCSS) [5]
demonstrated that children’s thyroid glands were particu-
larly susceptible to radiation during cancer therapy. A
* Correspondence: clauspix@uni-mainz.de
3German Childhood Cancer Registry, Institute of Medical Biostatistics,
Epidemiology and Informatics, University Medical Centre of the Johannes
Gutenberg University Mainz, Mainz 55101, Germany
Full list of author information is available at the end of the article
© 2015 Finke et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Finke et al. Radiation Oncology  (2015) 10:219 
DOI 10.1186/s13014-015-0521-6
pooled analysis of several epidemiological studies illus-
trated that the relative risk (RR) for thyroid cancer in-
creases with increasing radiation dose, up to 15-fold at an
estimated does of 10 Gy to the thyroid gland [6] compared
to patients with no radiation therapy. This analysis also
showed that the risk of thyroid cancer declines after high-
dose radiotherapy, but it is assumed that elevated risk
continues for many decades [6]. Based on these results, it
is expected that long-term survivors have an increased
risk of a subsequent thyroid cancer. Younger age at diag-
nosis, female sex and longer time since exposure to radi-
ation were found to increase this effect [5], but a meta-
analysis showed no modification of radiation effects by sex
[6]. Furthermore it is questionable if the tissue of thyroid
glands is specifically sensitive to the influence of radiation
in comparison to the entire neck region.
In this study, we analysed the relationship between
radiotherapy exposure of the neck region and the occur-
rence of cancer as a second solid tumour in relation to
cumulative radiation dose per body region (given dose).
The emphasis is on thyroid cancers; other cancers of the
neck region are investigated to assess the specificity of
the thyroid effect. The exposure data available are given
as the dose per body region, which allows exposure
region specificity to be investigated.
Methods
Study population
This paper presents a subgroup of the patients published
in [9, 10], where the patient groups are described in
detail. Briefly, the 33,809 patients with a childhood ma-
lignancy diagnosed from 1980 to 2000 registered in the
German Childhood Cancer Registry (GCCR) in 2003
served as basis for a nested case–control study [9]. As a
federal registry, case ascertainment by the GCCR per-
tains to all malignancies diagnosed in German residents
up to 14 years of age and has achieved a high degree of
completeness [1]. Patients are followed up indefinitely
with an emphasis on complete registration of subsequent
malignancies. SNs had been diagnosed before 06/30/
2002 and at least three months later than the first neo-
plasm (FN). The controls were patients who had not
experienced an SN by the date of selection and were
matched by sex, age at diagnosis, year at diagnosis and
follow-up time since FN. For the analysis presented here,
the SNs located in the neck region were selected: 17
thyroid cases, 12 other second neoplasm cases, 57
controls. All individuals included in this study gave
general informed consent at the time of being regis-
tered by the GCCR. At time of data retrieval, neither
active participation nor a specific ethics approval was
required, as only existing data from an approved data
base were used.
Therapy data
Information on therapy for the first cancer was available
for all cases and controls from medical records. The
body regions targeted by radiotherapy were classified
into 10 regions [10]. A given dose is defined as the radi-
ation dose in Gy applied to the respective body region.
The cumulative dose to each body region was calculated
as the sum of all given doses to this region. Absorbed
doses for body regions, organs or tissues were not
available.
Statistical analysis
Statistical analysis was conducted using conditional
logistic regression as appropriate for nested case control
studies. We used the given radiation doses as a continuous
variable, assuming a linear dose–response relationship
with log(OR). The effects of dose by region were assessed
as follows: The main model (Model 1) estimated the effect
of the dose given to the neck region. To identify other
relevant exposed regions, the respective cumulative
radiotherapy doses to every single other body region
were additionally included in the model, and the best
fitting combination was selected with a backward selection
procedure (cut off level p = 0.1) (Model 2). If more than
one exposed region had an effect, a combined model was
estimated (Model 3). Alternatively, the sums of the expos-
ure to all other body regions (Model 4) or adjacent body
regions of the neck (head, thorax and spine) only (Model
5) were included in the model in addition to the neck
dose. Results are expressed as odds ratios (OR) per Gy
with two-sided 95 % confidence intervals (CI).
A number of sensitivity analyses were performed:
Chemotherapy was investigated as a potential confounder
by including separate chemotherapeutical agent indicator
variables in the model. Alternative shapes of the
dose–response curve were tested according to Royston
et al. [11]. Potential effect modification by year of diagno-
sis, age at diagnosis, latency time or sex was analysed by
including categorised effect modifiers. Years (age, diagno-
sis, latency) were categorised in groups of 5 years.
Results
The second malignant thyroid cancers in the 17 cases
(10 males, 7 females) included papillary adenocarcinoma
(n = 12), follicular adenocarcinoma (n = 4), and one un-
specified adenocarcinoma. The 12 other second malignant
cancers located in the neck region included Hodgkin’s
lymphomas (n = 8), one non-Hodgkin’s lymphoma, one
fibrosarcoma and two other specified soft tissue sarcomas
(ICCC-3 IX(d)) (Table 1).
SNs in thyroid cases occurred between the ages of 8
and 30 years, and in other SN cases between ages 4 and
24 years. The median interval between the diagnosis of
the FN and the SN was 9.3 years (range 4.0-17.6 years)
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for thyroid cases and 4.3 years (range 1.6-14.5 years) for
other cases (Table 1).
The most frequent FNs among all neck SN cases were
leukaemias and lymphomas (Table 1), while most frequent
FNs among the controls were leukaemias, lymphomas and
renal tumours (Table 2).
16 of 17 the thyroid SN cases (94.1 %), 9 of 12 other
neck SN cases (75 %) and 34 of 57 controls (59.6 %) had
received radiotherapy to at least one body region with a
median cumulative dose over all body regions of 27.8, 25
and 24 Gy respectively (Table 3).
Four thyroid SN cases (23.5 %), 3 other neck SN cases
(25 %) and 4 controls (7 %) had received radiotherapy to
the neck region with respective median doses to the
neck region of 30.3, 35 and 32.5 Gy, ranging from
20–40 Gy (Table 3); all these patients had Hodgkin’s
Lymphoma as the FN. All 17 thyroid SN cases, all 12
of the other neck SN cases and 50 of the controls
(87.7 %) were exposed to chemotherapy.
Radiotherapy exposure to the neck region increased
the risk of thyroid cancer by OR RT(Neck) = 1.051/Gy
(95 %-CI 0.984-1.123) and other neck SNs OR RT(Neck) =
Table 1 Characteristics of cases with an SN in neck region by FN































interval FN to SN
in years (range)
I Leukaemias 8 8 4.5 (1–14) 15.5 (8–30) 11.5 (7.4-16.6) 7 5 4 (2–13) 8(4–17) 4 (1.6-6.1)
II Lymphomas 5 4 10 (7–13) 19 (14–25) 7.3 (4.0-17.6) 3 3 12 (8–14) 20 (18–24) 12.5 (4.2-12.9)
III CNS tumours 2 2 3.5 (2–5) 13 (11–15) 9.1 (8.9-9.3) 0 - - - -
IV Neuroblastomas 0 - - - - 1 0 0 (−) 4 (−) 3.6 (−)
VI Renal tumours 1 1 3 (−) 12 (−) 8.5 (−) 1 1 0 (−) 15 (−) 14.5 (−)
IX Soft tissue
sarcomas
1 1 1 (−) 13 (−) 11.5 (−) 0 - - - -
Total All FN 17 16 5 (1–14) 15 (8–30) 9.3 (4.0-17.6) 12 9 4.5 (0–14) 12 (4–24) 4.3 (1.6-14.5)
CNS: central nervous system
FN: first neoplasm
HL: Hodgkin’s Lymphoma




STS: Soft Tissue Sarcoma
Characteristics of 17 cases with SN of the thyroid and 12 cases with any other neck SN diagnosed 1980–2002 by FN (ICCC-3 classification [1]) diagnosed
in 1980–2000 in Germany, FN below the age of 15
Table 2 Characteristics of 57 matched controls
ICCC group First cancer type Controls n RT+ n Median age at diagnosis of FN (range)
I Leukaemias 22 18 5 (1–14)
II Lymphomas 12 7 9 (1–14)
III CNS tumours 6 3 5.5 (4–13)
IV Neuroblastoma 1 0 1 (−)
VI Renal tumours 9 3 1 (1–12)
VII Hepatic tumours 1 0 0 (−)
VIII Bone tumours 1 1 3 (−)
IX Soft tissue sarcomas 2 1 4.5 (4–5)
X Germ cell tumours 2 0 1 (0–2)
Other non-malignant neoplasm 1 1 14 (−)
Total All FNs 57 34 5 (0–14)
CNS: central nervous system
FN: first neoplasm
ICCC: International Classification of Childhood Cancer
RT+: radiotherapy received
Characteristics of 57 matched controls by FN (ICCC-3 classification [1]) diagnosed in 1980–2000 in Germany, aged under 15 years
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1.042/Gy (95 %-CI 0.980-1.109) (Model 1, Table 4). This
means that people exposed to 20 Gy had a 2.703-fold
risk increase and a 4.51-fold risk increase at 30.3 Gy
(median dose given at the neck) for a thyroid SN.
Exploring the exposure of other body regions, a com-
bination of neck and spine exposure is associated with
thyroid cancer cases (OR RT(Neck or spine) =1.066 (95 %-CI
1.010-1.125)) (Model 3, Table 4), while only the neck re-
gion exposure is relevant for other neck region SNs
(Model 2, Table 4). The additional cumulative doses of
all other or all adjacent body regions do not have an ef-
fect on thyroid or other neck region SNs (Model 4 and
5, Table 4).
The model for all second neck cancers was not im-
proved by adding exposure to other body regions into
the model.
Regarding the dose–response relationship between
radiotherapy and risk of subsequent thyroid cancer, a
linear relationship with the log(OR) could be seen in our
study. Figure 1 shows the dose–response relationship
from Model 3 for thyroid SNs. Other dose response
curves were rejected in the sensitivity analysis.
There was no change in the effect of radiotherapy
when including chemotherapy in the thyroid SN model;
chemotherapy had no independent effect on the risk of a
second thyroid or other neck region tumour either. Risk
estimates were similar in all age groups, for male and
female, for year of diagnosis and for latency years (data
not shown). However, data are too sparse to investigate
effect modification effects in depth.
Discussion
Results from our small nested case–control study show
that radiotherapy applied to the neck region increases
the risk of a second tumour in the thyroid gland by
5.1 % per one Gy total given dose, and radiotherapy ap-
plied to the neck or spine region significantly increased
the risk by 6.6 % per one Gy of the total dose given.
Radiotherapy in the neck region had a similar, though
slightly smaller, effect on the risk of other SNs in the
neck region (4.2 %/Gy).
It must be noted that neither exposure to the thorax
nor to the head had an effect on thyroid SNs (or other
neck SNs) in addition to exposure to the neck, although
most patients with exposure to the neck also had a head
and/or thorax exposure due to their Hodgkin’s lymph-
oma treatment protocols. Most patients with spinal
exposure were primary leukaemia patients. Radiotherapy
given to regions other than the neck or spine did not
seem to further increase the risk of SNs in the neck
region. Confounding by chemotherapy was not present.
The sample was too small to detect differences between
subgroups.
Table 3 Body regions exposed to radiotherapy and median cumulative exposure













controls in Gy (min-max)
Head 10 19 (18–55) 4 12 (12–30) 27 24 (12–110)
Neck 4 30.3 (25–35) 3 35 (30–35) 4 32.5 (20–40)
Spine 4 24 (18–35) 2 24 (−) 6 29.6 (15–40)
Neck or spinea) 8 25.3 (18–35) 5 30 (24–35) 10 30.1 (15–40)
Thorax 2 25.3 (25–25.6) 2 35 (−) 4 30.5 (20–40)
Abdomen 1 30 (−) 1 25 (−) 7 25 (20–36)
Pelvis 1 32 (−) 0 - 0 -
Legs 0 - 0 - 0 -
Arms 0 - 0 - 0 -
Unexposed 1 - 3 - 23 -
Total exposed (Max
exposure per person)




ICCC: International Classification of Childhood Cancer
NHL: Non-Hodgkin’s Lymphoma
SN: second neoplasm
STS: Soft Tissue Sarcoma
a): Exposed individuals are either neck or spine exposed, never both
Exposed body regions of 29 cases with SN of the thyroid or any other neck SN diagnosed 1980–2002 and 57 matched controls by FN (ICCC-3 classification [1])
diagnosed in 1980–2000 in Germany, FN at age under 15 years
Finke et al. Radiation Oncology  (2015) 10:219 Page 4 of 7
We conclude that the risk of a second neoplasm in the
neck region increases specifically with radiotherapy
exposures in the neck (and spine) region but not with
exposure to other body regions. Furthermore the effect
is not entirely specific to thyroid tumours: the risk of
other second tumours, such as lymphomas and sarcomas,
is almost as high per dose given.
The results are not quite comparable to results of
other studies on subsequent thyroid cancer after child-
hood cancer [5, 6, 12]. Bhatti et al. [5] described a non-
monotonous relationship, with estimated absorbed thyroid
doses of up to 60 Gy, peaking at 20 Gy. A previous ana-
lysis by Ronckers et al. [12] found a similar dose response
curve. Veiga et al. [6] pooled data from US, UK, Nordic
and Canadian studies (including the aforementioned study
by Bhatti et al. [5]) and found a similar dose response
curve. Fitted RR for 20 Gy in all three cited studies are
about 13 to 15 fold compared to 2.7 fold in this study.
However, the pooled study also shows that estimates in
different study groups vary widely, and different dose re-
sponse curves have a surprisingly similar fit. The sensitiv-
ity modelling did not show a preference in our data for a
non-monotonous dose response relationship, including a
peaked curve (see also Fig. 1). However, the number of
exposed cases, particularly exposed cases with doses of
30 Gy or more, was basically too small to fit more com-
plex models. It is difficult to compare given doses to
absorbed doses; however, as an example, for Hodgkin
Lymphoma patients Gul et al. [7] estimate that 64-94 % of
the given dose is also absorbed by the thyroid.
Fig. 1 Dose–response relationship. Dose–response relationship odds
ratio (OR) of thyroid SN and cumulative radiotherapy given dose in
the neck or spine region in 51 German childhood cancer survivors
(17 SN cases, 34 controls) first diagnosed in 1980–2000. The line is
the regression result. The bubbles are OR estimates of grouped dose
data for illustration purposes. Mean dose per dose group is given on
the horizontal axis. Bubble sizes are proportional to the number of
patients per dose group
Table 4 Conditional logistic regression analysis
Thyroid SN (17 cases, 34
controls)
Any other neck SNs
(8 HL, 1 NHL, 3 STS)
(12 cases, 23 controls)
Any neck SN (29 cases,
57 controls)
Model Odds ratio/1 Gy 95 % CI Odds ratio/1 Gy 95 % CI Odds ratio/1 Gy 95 % CI
1 RT dose in region of SN (neck) 1.051 0.984-1.123 1.042 0.980-1.109 1.046 1.000-1.095
2 RT dose in region of SN (neck) 1.057 0.992-1.127 1.042 0.979-1.109 1.051 1.004-1.101
RT dose in region of spine 1.080 0.994-1.173 0.995 0.931-1.063 1.031 0.985-1.079
3 RT dose in region of spine or neck 1.066 1.010-1.125 1.019 0.974-1.067 1.041 1.006-1.078
4 RT dose in region of SN (neck) 1.048 0.980-1.120 1.045 0.981-1.113 1.046 1.000-1.095
Cumulative RT dose in other body regions 1.004 0.983-1.027 0.988 0.949-1.029 1.000 0.982-1.019
5 RT dose in region of SN (neck) 1.045 0.979-1.116 1.043 0.980-1.110 1.045 0.999-1.093









STS: Soft Tissue Sarcoma
ahead, thorax, spine
Results from conditional logistic regression analysis of effect of RT doses in the region of the neck, all other regions or at regions adjacent to the neck in 17 cases
with SN of the thyroid and 12 cases of any other neck SN diagnosed 1980–2002 and 57 matched controls by FN (ICCC-3 classification [1]) diagnosed in 1980
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The median time interval for the occurrence of second
thyroid cancer was 9.3 years (Min 4.0 years, max
17.8 years) in this study. However, follow-up is some-
what shorter compared to other studies, which reported
latency periods of 12.5 to 19 years [3, 5, 13–15].
Chemotherapy was not found to be a confounder for
the association between radiotherapy and thyroid cancer
risk, which is consistent with findings of Bhatti et al. [5]
but inconsistent with Veiga et al. [6], who found an
effect modification of chemotherapy for alkylating
agents, anthracyclins and bleomycin.
While this study was too small to show effect modifi-
cation by age, sex, year or latency, the previous study by
Hennewig et al. [10], assessing all solid second tumours,
showed a higher risk per radiotherapy dose for cases
younger at first diagnosis, diagnosed earlier (1980’s as
opposed to the 1990’s) and after a longer latency period,
but not by sex. Age and latency as effect modifiers were
also reported by other studies on subsequent thyroid
cancer [3, 5]. Bhatti et al. [5] reported a higher risk of
SN of the thyroid gland in women, in which they saw a
reflection of the generally higher proportion of females
in the population of thyroid cancer patients. The
meta-analysis by Veiga et al. [6] showed no modifica-
tion of radiation effects by sex.
Our study has several strengths and limitations. The
main limitation of this study is the small number of
cases. However, a notable risk increase could be shown
nonetheless. The follow-up time of maximally 18 years
of the cases was rather short; more subsequent thyroid
cancer cases are expected from this cohort with further
follow-up.
One of this study’s strengths is that it is an unselected
cohort from a fairly complete population-based registry
representative for the German population of childhood
cancer patients [1]. All known cases with a malignant
second neoplasm of the thyroid gland observed between
1980–2002 in Germany after a first childhood neoplasm
were included, and their controls were chosen from the
same database. The other strength is the recording of
the dose data by body regions, which allows the contri-
bution of the exposure of all body regions to the risk of
thyroid SNs and other neck SNs to be assessed separ-
ately and jointly.
Conclusion
Our results indicate that radiotherapy exposure of the
neck or spine region in childhood can be related to the
occurrence of thyroid cancer as an SN as early as 4 years
later. For neck radiation exposure, the risk of other SNs
in the neck region (lymphomas, sarcomas) occurring
even earlier is almost as large as for second thyroid can-
cer. The sample was small; however, the study group is
unselected and well defined. Childhood cancer survivors
treated with radiotherapy to the neck and spine region
should be followed up closely for SNs in the thyroid,
despite the pros and cons of thyroid screening [16].
Other subsequent cancers may also occur in an irradi-
ated neck region.
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